In: Obesity
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Obesity
- Main trialPhase 2
- “This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.”In the company’s words, NCT06577090 on ClinicalTrials.gov
Other drugs for Obesity
- CagriSemaNovo Nordisk · Filed (US)
- HRS-7535Hengrui · Kailera · Filed (China)
- RibupatideHengrui · Kailera · Filed (China)
- RetatrutideEli Lilly · Phase 3
- IN-B00009HK inno.N · Phase 3
- UBT251United Laboratories · Novo Nordisk · Phase 3
Coming up1
- 20 NovPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 20 Nov 2026 | Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026